Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Stayble Therapeutics looks towards its most important year so far

Stayble Therapeutics

2023 has been an eventful year for Stayble Therapeutics with positive interim data from the study in degenerative disc disease, a rights issue, launch of disc herniation as new indication and successful partnering discussions at the Bio International Convention in Boston. The company has also recruited two new key players to the team, Dr. Jarkko Kalliomäki and Professor Daisuke Sakai. However, this is only the beginning of 2023, which could be the most important year so far for the company, according to CEO Andreas Gerward.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/06/stayble-therapeutics-looks-towards-its-most-important-year-so-far/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.